- Alexion Pharmaceuticals (ALXN) waits for approval to sell its blockbuster drug Soliris in the UK.
- The National Institute for Health and Clinical Excellence (NICE) wants to examine the company's R&D costs for the drug to help it determine the appropriate reimbursement, considering its high cost.
- Soliris is the most expensive drug in the world. Annual treatment cost runs £340,000 (US$569,000).
- NICE's evaluation of the cost/benefits of the product falls under its new "ultra orphan" disease treatment review process. For Soliris, it has taken three years with no end in sight.
- There are ~170 patients in the UK that would be eligible for Soliris, representing a cost to the National Health Service of 58M Pounds ($97M).
- Soliris sales were $1.6B last year, with a forecast of $3.4B by 2018.
at Zacks.com (Nov 17, 2014)